Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California. more
Time Frame | GOSS | Sector | S&P500 |
---|---|---|---|
1-Week Return | 0.02% | -0.94% | -2.6% |
1-Month Return | 22.71% | -5.08% | -1.08% |
3-Month Return | -14.2% | -10.62% | 3.45% |
6-Month Return | 3.86% | -6.18% | 8.57% |
1-Year Return | -1.15% | 1.98% | 24.3% |
3-Year Return | -92.63% | -0.93% | 25.58% |
5-Year Return | -94.77% | 33.84% | 84.07% |
10-Year Return | -95.22% | 102.52% | 185.12% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 3.09M | 4.27M | 5.17M | 4.43M | 4.38M | [{"date":"2019-12-31","value":59.78,"profit":true},{"date":"2020-12-31","value":82.6,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":85.72,"profit":true},{"date":"2023-12-31","value":84.87,"profit":true}] |
Gross Profit | (3.09M) | (4.27M) | (5.17M) | (4.43M) | (4.38M) | [{"date":"2019-12-31","value":-308900000,"profit":false},{"date":"2020-12-31","value":-426800000,"profit":false},{"date":"2021-12-31","value":-516700000,"profit":false},{"date":"2022-12-31","value":-442900000,"profit":false},{"date":"2023-12-31","value":-438500000,"profit":false}] |
Gross Margin | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | [{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}] |
Operating Expenses | 182.54M | 210.58M | 216.05M | 218.53M | 183.76M | [{"date":"2019-12-31","value":83.53,"profit":true},{"date":"2020-12-31","value":96.36,"profit":true},{"date":"2021-12-31","value":98.87,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":84.09,"profit":true}] |
Operating Income | (186.14M) | (233.96M) | (216.12M) | (218.59M) | (183.76M) | [{"date":"2019-12-31","value":-18613900000,"profit":false},{"date":"2020-12-31","value":-23396200000,"profit":false},{"date":"2021-12-31","value":-21612400000,"profit":false},{"date":"2022-12-31","value":-21859300000,"profit":false},{"date":"2023-12-31","value":-18375900000,"profit":false}] |
Total Non-Operating Income/Expense | - | (18.62M) | (36.56M) | (23.08M) | (7.51M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-1862200000,"profit":false},{"date":"2021-12-31","value":-3655900000,"profit":false},{"date":"2022-12-31","value":-2308200000,"profit":false},{"date":"2023-12-31","value":-750600000,"profit":false}] |
Pre-Tax Income | (180.31M) | (243.36M) | (234.00M) | (229.38M) | (179.82M) | [{"date":"2019-12-31","value":-18030700000,"profit":false},{"date":"2020-12-31","value":-24336000000,"profit":false},{"date":"2021-12-31","value":-23400400000,"profit":false},{"date":"2022-12-31","value":-22937800000,"profit":false},{"date":"2023-12-31","value":-17981700000,"profit":false}] |
Income Taxes | 511.00K | 8.22M | 15.07M | 10.85M | 10.00M | [{"date":"2019-12-31","value":3.39,"profit":true},{"date":"2020-12-31","value":54.56,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":71.99,"profit":true},{"date":"2023-12-31","value":66.35,"profit":true}] |
Income After Taxes | - | (251.58M) | (249.08M) | (240.23M) | (189.82M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-25158400000,"profit":false},{"date":"2021-12-31","value":-24907600000,"profit":false},{"date":"2022-12-31","value":-24022800000,"profit":false},{"date":"2023-12-31","value":-18981700000,"profit":false}] |
Income From Continuous Operations | (180.31M) | (243.36M) | (234.00M) | (229.38M) | (187.43M) | [{"date":"2019-12-31","value":-18030700000,"profit":false},{"date":"2020-12-31","value":-24336000000,"profit":false},{"date":"2021-12-31","value":-23400400000,"profit":false},{"date":"2022-12-31","value":-22937800000,"profit":false},{"date":"2023-12-31","value":-18743300000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (180.82M) | (251.58M) | (249.08M) | (240.23M) | (179.82M) | [{"date":"2019-12-31","value":-18081800000,"profit":false},{"date":"2020-12-31","value":-25158400000,"profit":false},{"date":"2021-12-31","value":-24907600000,"profit":false},{"date":"2022-12-31","value":-24022800000,"profit":false},{"date":"2023-12-31","value":-17981700000,"profit":false}] |
EPS (Diluted) | (3.33) | (3.55) | (3.12) | (2.74) | (1.39) | [{"date":"2019-12-31","value":-333,"profit":false},{"date":"2020-12-31","value":-355,"profit":false},{"date":"2021-12-31","value":-312,"profit":false},{"date":"2022-12-31","value":-274,"profit":false},{"date":"2023-12-31","value":-139,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
GOSS | |
---|---|
Cash Ratio | 6.40 |
Current Ratio | 6.74 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
GOSS | |
---|---|
ROA (LTM) | -11.24% |
ROE (LTM) | -90.26% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
GOSS | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.85 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.15 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
GOSS | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 1.81 |
P/B | 3.52 |
Price/FCF | NM |
EV/R | 0.64 |
EV/Ebitda | NM |
Gossamer Bio Inc (GOSS) share price today is $0.858
Yes, Indians can buy shares of Gossamer Bio Inc (GOSS) on Vested. To buy Gossamer Bio Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in GOSS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Gossamer Bio Inc (GOSS) via the Vested app. You can start investing in Gossamer Bio Inc (GOSS) with a minimum investment of $1.
You can invest in shares of Gossamer Bio Inc (GOSS) via Vested in three simple steps:
The 52-week high price of Gossamer Bio Inc (GOSS) is $1.6. The 52-week low price of Gossamer Bio Inc (GOSS) is $0.5.
The price-to-earnings (P/E) ratio of Gossamer Bio Inc (GOSS) is
The price-to-book (P/B) ratio of Gossamer Bio Inc (GOSS) is 3.52
The dividend yield of Gossamer Bio Inc (GOSS) is 0.00%
The market capitalization of Gossamer Bio Inc (GOSS) is $190.35M
The stock symbol (or ticker) of Gossamer Bio Inc is GOSS